Whitehawk Therapeutics (WHWK)
NASDAQ:WHWK
Want to see WHWK full AI Analyst Report?
WHWK Stock Chart & Stats
$4.11
--
Market closed
$4.11
--
Day’s Range― - ―
52-Week Range$1.39 - $4.48
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.35M
Market Cap
$199.64M
Enterprise Value$160.66M
Total Cash (Recent Filing)$145.70M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.91
Next Earnings
May 07, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding47,196,564
10 Day Avg. Volume9,835,549
30 Day Avg. Volume3,352,856
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.10
Price to Sales (P/S)20.96
P/FCF Ratio-1.53
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue22.49
Enterprise Value/Gross Profit25.19
Enterprise Value/Ebitda-1.46
Forecast
1Y Price Target
$7.00Price Target Upside70.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
ADC Design AdvantagesBiparatopic SEZ6 design and membrane-targeting HWK-016 aim to increase target specificity and internalization, potentially widening the therapeutic window versus earlier therapies.
Clinical AdvancementEntry of PTK7 and MUC16 programs into clinical trials moves the pipeline toward clinical proof of concept and may validate the company's ADC platform.
Regulatory MilestoneIND submission for a SEZ6-targeted antibody-drug conjugate would enable first-in-human studies and could attract renewed investor interest in the program.
Bears Say
Clinical Safety RiskPrior ADC programs were limited by serious toxicities and concerns about topoisomerase I-related adverse events, creating a meaningful safety overhang for development programs.
Commercial And Dilution RiskRisk of limited market uptake in niche indications, failure to expand into additional cancer types, competitive pressure and potential share dilution could constrain commercial returns.
Early-stage Valuation RiskAnalysts excluding early-stage assets from valuation due to lack of clinical efficacy data keep upside uncertain until human results are available.
Whitehawk Therapeutics News
WHWK FAQ
What was Whitehawk Therapeutics’s price range in the past 12 months?
Whitehawk Therapeutics lowest stock price was $1.39 and its highest was $4.48 in the past 12 months.
What is Whitehawk Therapeutics’s market cap?
Whitehawk Therapeutics’s market cap is $199.64M.
When is Whitehawk Therapeutics’s upcoming earnings report date?
Whitehawk Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 15 days.
How were Whitehawk Therapeutics’s earnings last quarter?
Whitehawk Therapeutics released its earnings results on Mar 12, 2026. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.483 by $0.143.
Is Whitehawk Therapeutics overvalued?
According to Wall Street analysts Whitehawk Therapeutics’s price is currently Undervalued.
Does Whitehawk Therapeutics pay dividends?
Whitehawk Therapeutics does not currently pay dividends.
What is Whitehawk Therapeutics’s EPS estimate?
Whitehawk Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Whitehawk Therapeutics have?
Whitehawk Therapeutics has 47,196,564 shares outstanding.
What happened to Whitehawk Therapeutics’s price movement after its last earnings report?
Whitehawk Therapeutics reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.483. Following the earnings report the stock price went down -2.743%.
Which hedge fund is a major shareholder of Whitehawk Therapeutics?
Currently, no hedge funds are holding shares in WHWK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Whitehawk Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (70.32% Upside)
$7.00 (70.32% Upside)
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.79%
12-Months-Change
Fundamentals
Return on Equity
-11.99%
Trailing 12-Months
Asset Growth
113.47%
Trailing 12-Months
Company Description
Whitehawk Therapeutics
Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
WHWK Stock 12 Month Forecast
Average Price Target
$7.00
▲(70.32% Upside)
Technical Analysis
Ownership Overview
28.27% Insiders
4.19% Mutual Funds
61.65% Other Institutional Investors
2.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---